溶瘤病毒療法市場－全球產業規模、佔有率、趨勢、機會及預測（按病毒類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球溶瘤病毒療法市場預計將從 2025 年的 4,973 萬美元成長到 2031 年的 1.5331 億美元，複合年成長率為 20.64%。

這個專門的癌症治療領域利用天然或基因工程改造的病毒，這些病毒旨在選擇性地複製並摧毀惡性細胞，同時誘導廣泛的抗腫瘤免疫反應。推動該市場發展的關鍵因素包括難治性癌症發生率的上升以及臨床上迫切需要毒性低於傳統療法的標靶治療。此外，基因改造技術的不斷進步使得開發具有更高特異性和效力的病毒成為可能，進一步促進了相關研發工作。

根據美國基因與細胞治療學會2024年的數據，全球基因、細胞和RNA療法的開發平臺超過4,000個，這數字顯示目前大量投資正湧入溶瘤病毒等先進治療方法。儘管發展勢頭強勁，但市場成長仍面臨宿主免疫系統的重大挑戰。預先存在的免疫反應以及人體對病毒的快速清除，可能導致治療在有效清除靶向癌細胞之前就失效，從而對療效構成重大挑戰。

市場促進因素

推動全球溶瘤病毒療法市場發展的主要因素是全球癌症和固態腫瘤負擔的日益加重，這使得臨床上迫切需要能夠克服晚期疾病中常見的抗藥性的藥物。美國癌症協會在2025年1月發布的《2025年癌症事實與數據》報告中預測，到2025年，美國新增癌症病例將達到2,041,910例，凸顯了日益嚴重的疾病負擔。患者數量的增加促使大規模資本投資湧入，旨在加速藥物研發管線的開發。例如，Labiotech.eu在2025年8月報道稱，Tilt Biotherapeutics於2025年5月完成了2,500萬美元的B輪資金籌措，用於進一步開發其候選藥物TILT-123。這顯示業界正致力於利用新型病毒製劑來滿足這些臨床需求。

同時，協同聯合治療的日益普及正在重塑市場格局，尤其是溶瘤病毒與查核點抑制劑的聯合療法。這些病毒正被擴大用於改變腫瘤微環境，從而有效提高免疫「冷」腫瘤對查核點阻斷療法的敏感性。這項策略得到了令人信服的臨床數據支持。根據Replimune集團2025年6月發布的題為「Replimune公佈最新分析結果」的新聞稿，RP1與Nivolumab聯合治療在接受抗PD-1治療失敗的黑色素瘤患者中實現了75.3%的1年生存率。如此強勁的結果支持了這些聯合治療的商業性和治療潛力，並推動其被納入未來的標準腫瘤治療通訊協定。

市場挑戰

宿主免疫系統構成了一道強大的生物屏障，顯著阻礙了溶瘤病毒療法的療效和商業性進程。當治療性病毒被注射到體內時，患者的先天性和適應性免疫系統通常會將其識別為病原體，並迅速產生中和抗體。這種免疫反應往往會在病毒能夠在腫瘤內充分複製或誘導預期腫瘤溶解之前將其從體內清除，導致臨床療效不穩定，並降低了整體治療方法的可靠性。

這項挑戰直接阻礙了市場成長，導致臨床開發階段的高脫落率，並需要高成本大量時間和成本進行研究。將有前景的臨床前結果轉化為核准療法的困難，造成了產品平臺的重大瓶頸，後期成功案例遠少於早期階段的案例便印證了這一點。根據再生醫學聯盟2024年的報告，預計全球僅有17個項目將接近監管部門的核准。如此有限的候選藥物即將上市，凸顯了早期病毒清除等生物學障礙如何限制了全球溶瘤病毒療法市場的擴充性和獲利能力。

市場趨勢

該領域的顯著成熟體現在病毒載體平台已不再局限於單純皰疹病毒（HSV）。研發人員正積極探索具有獨特免疫抗原性原性的替代載體，例如腺病毒和痘苗病毒。這種轉變使得針對特定腫瘤類型客製化病毒載體平台成為可能，從而克服了第一代療法的局限性。這些非HSV載體平台的商業性可行性得到了可靠的後期臨床數據支持。根據Kandel Therapeutics公司於2025年3月發布的“2024年第四季度及全年財務業績”，該公司基於腺病毒的候選藥物CAN-2409已在一項涉及496名患者的3期臨床試驗中得到評估，這表明該公司明確致力於拓展其病毒載體療法的種類。

同時，為了克服腫瘤內注射的局限性，人們正轉向全身靜脈注射機制，這為轉移性疾病的治療開啟了新的可能性。新一代病毒平台旨在能夠在血液中存活，逃避中和作用，並主動標靶化轉移性腫瘤部位。這種從局部到全身給藥的轉變顯著擴大了目標患者群體，並使病毒療法與標準的腫瘤輸注流程相容。根據Oncolytics Biotech公司於2024年12月發布的「Oncolytics Biotech 2024會計年度業績亮點」新聞稿，在BRACELET-1試驗中，靜脈注射Pelareorep與單獨化療相比，預計可使患者的中位總生存期延長一年以上，這支持了全身病毒給藥的治療效果。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球溶瘤病毒療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依病毒類型（基因改造溶瘤病毒、野生型溶瘤病毒）
  • 依應用領域（肺癌、乳癌、結腸癌、黑色素瘤、攝護腺癌、頭頸癌、卵巢癌、胰臟癌、其他癌症）
  • 按最終使用者（醫院/診所、癌症研究中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美溶瘤病毒療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲溶瘤病毒療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區溶瘤病毒療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲溶瘤病毒療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲溶瘤病毒療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球溶瘤病毒療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Immunocore Holdings plc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Oncolytic Virotherapy Market is projected to expand from USD 49.73 Million in 2025 to USD 153.31 Million by 2031, registering a CAGR of 20.64%. This specialized field of cancer treatment utilizes native or genetically engineered viruses designed to selectively replicate within and destroy malignant cells while simultaneously triggering a wider antitumor immune response. Major factors driving this market include the rising incidence of refractory cancers and the urgent clinical need for targeted therapies that offer lower toxicity than conventional treatments. Additionally, ongoing advancements in genetic modification techniques are enabling the creation of viruses with greater specificity and potency, further fueling development efforts.

According to data from the 'American Society of Gene & Cell Therapy' in '2024', the global pipeline for gene, cell, and RNA therapies included over 4,000 active candidates, a figure that highlights the massive investment currently flowing into advanced modalities such as oncolytic viruses. Despite this strong momentum, market growth faces a substantial hurdle in the form of the host immune system. Preexisting immunity or the body's rapid clearance of the virus can neutralize the therapy before it has the opportunity to effectively eliminate the targeted tumor cells, posing a significant challenge to efficacy.

Market Driver

The primary engine propelling the Global Oncolytic Virotherapy Market is the escalating global burden of cancer and solid tumors, which creates an acute clinical need for agents capable of overcoming the resistance often seen in late-stage disease. The 'American Cancer Society' projected in its 'Cancer Facts & Figures 2025' report (January 2025) that there would be 2,041,910 new cancer cases in the United States in 2025, underscoring the intensifying disease burden. This increasing patient volume has triggered substantial financial investments aimed at accelerating pipeline development; for example, Labiotech.eu reported in August 2025 that Tilt Biotherapeutics secured a $25 million Series B financing round in May 2025 to advance its candidate TILT-123, demonstrating the industry's dedication to meeting these clinical needs with novel viral agents.

Simultaneously, the market landscape is being reshaped by the growing adoption of synergistic combination therapies, particularly those pairing oncolytic viruses with checkpoint inhibitors. These viruses are increasingly used to modify the tumor microenvironment, effectively sensitizing immunologically cold tumors to checkpoint blockade. This strategy is supported by compelling clinical data; according to a June 2025 press release titled 'Replimune Presents New Analyses' by Replimune Group, Inc., the combination of RP1 and nivolumab resulted in a 75.3% 1-year overall survival rate in patients with anti-PD1 failed melanoma. Such robust results validate the commercial and therapeutic potential of these combination regimens, driving their incorporation into future standard oncology protocols.

Market Challenge

The host immune system represents a formidable biological barrier that significantly hinders the efficacy and commercial advancement of oncolytic virotherapy. When therapeutic viruses are administered, the patient's innate and adaptive immune systems often recognize them as pathogens, rapidly generating neutralizing antibodies. This immune response frequently clears the virus from the body before it can sufficiently replicate within the tumor or induce the intended oncolysis, leading to inconsistent clinical results and undermining the overall reliability of the therapy.

This challenge directly stifles market growth by causing high attrition rates during clinical development and necessitating prolonged, expensive research cycles. The difficulty in translating promising preclinical findings into approved therapies creates a severe bottleneck in the product pipeline, evidenced by the low number of late-stage successes compared to early-stage activity. According to the 'Alliance for Regenerative Medicine' in '2024', the sector expected only '17 programs' to near regulatory approval globally. This limited volume of near-market candidates highlights how biological hurdles, such as premature viral clearance, restrict the scalability and revenue potential of the global oncolytic virotherapy market.

Market Trends

A significant maturation in the sector is marked by the diversification of viral platforms beyond Herpes Simplex Virus, as developers increasingly explore alternative vectors like adenovirus and vaccinia for their unique immunogenic profiles. This shift enables the tailoring of viral backbones to specific tumor types, addressing the limitations associated with first-generation therapies. The commercial viability of these non-HSV platforms is supported by robust late-stage data; according to Candel Therapeutics in March 2025 regarding their 'Fourth Quarter and Full Year 2024 Financial Results', the company's adenovirus-based candidate, CAN-2409, was evaluated in a Phase 3 arm of 496 patients, demonstrating a clear clinical focus on expanding the repertoire of viral modalities.

Concurrently, there is a transition toward systemic intravenous delivery mechanisms to overcome the limitations of intratumoral injection, thereby opening new possibilities for treating metastatic disease. Next-generation viral platforms are being engineered to survive in the bloodstream, evade neutralization, and actively target disseminated tumor sites. This evolution from local to systemic administration significantly broadens the addressable patient population and aligns virotherapy with standard oncology infusion workflows. As reported by Oncolytics Biotech in December 2024 in their 'Oncolytics Biotech Highlights 2024 Achievements' press release, the intravenous administration of pelareorep in the BRACELET-1 study yielded an estimated median overall survival benefit exceeding one year compared to chemotherapy alone, confirming the therapeutic viability of systemic viral delivery.

Key Market Players

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Immunocore Holdings plc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.

Report Scope

In this report, the Global Oncolytic Virotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncolytic Virotherapy Market, By Virus Type

• Genetically Engineered Oncolytic Virus
• Oncolytic Wild Type Virus

Oncolytic Virotherapy Market, By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Others

Oncolytic Virotherapy Market, By End User

• Hospitals & Clinics
• Cancer Research Centers
• Others

Oncolytic Virotherapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncolytic Virotherapy Market.

Available Customizations:

Global Oncolytic Virotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncolytic Virotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Virus Type (Genetically Engineered Oncolytic Virus, Oncolytic Wild Type Virus)
  • 5.2.2. By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Cancer Research Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Oncolytic Virotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Virus Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oncolytic Virotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Virus Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Oncolytic Virotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Virus Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Oncolytic Virotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Virus Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Oncolytic Virotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Virus Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oncolytic Virotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Virus Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Oncolytic Virotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Virus Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Oncolytic Virotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Virus Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Oncolytic Virotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Virus Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Oncolytic Virotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Virus Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Oncolytic Virotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Virus Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oncolytic Virotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Virus Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Oncolytic Virotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Virus Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Oncolytic Virotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Virus Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Oncolytic Virotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Virus Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Oncolytic Virotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Virus Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Oncolytic Virotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Virus Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oncolytic Virotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Virus Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Oncolytic Virotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Virus Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Oncolytic Virotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Virus Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Oncolytic Virotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Virus Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oncolytic Virotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Virus Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Oncolytic Virotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Virus Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Oncolytic Virotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Virus Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oncolytic Virotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. GlaxoSmithKline plc
• 15.4. Immunocore Holdings plc.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. AstraZeneca
• 15.7. Merck & Co., Inc.
• 15.8. Boehringer Ingelheim GmbH
• 15.9. Bristol-Myers Squibb Company
• 15.10. Johnson & Johnson Services, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer